Nephrocare Health Services Limited (NSE:NEPHROPLUS)

Market Cap	69.65B
Revenue (ttm)	10.54B +39.4%
Net Income	851.10M +26.8%
EPS	8.63 +7.7%
Shares Out	100.34M
PE Ratio	80.43
Forward PE	40.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,681
Open	681.25
Previous Close	674.15
Day's Range	673.00 - 695.85
52-Week Range	446.00 - 769.75
Beta	n/a
Analysts	Buy
Price Target	822.50 (+18.5%)
Earnings Date	Aug 11, 2026

About NSE:NEPHROPLUS

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2009
• Employees: 2,294
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NEPHROPLUS

Financial Performance

In fiscal year 2026, NSE:NEPHROPLUS's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.

Analyst Summary

According to 4 analysts, the average rating for NEPHROPLUS stock is "Buy." The 12-month stock price target is ₹822.50, which is an increase of 18.50% from the latest price.

Price Target

₹822.50

(18.50% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 22, 2026

Data Sources Report a data error